Apnimed, a developer of pharmacologic treatments for sleep apnea and related disorders, has raised $25 million in Series B financing. Morningside Ventures led the round with participation from Seligman Investments and Tao Capital Partners.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: